WO2007044796A3 - Pyridazinone compounds as calcilytics - Google Patents

Pyridazinone compounds as calcilytics Download PDF

Info

Publication number
WO2007044796A3
WO2007044796A3 PCT/US2006/039700 US2006039700W WO2007044796A3 WO 2007044796 A3 WO2007044796 A3 WO 2007044796A3 US 2006039700 W US2006039700 W US 2006039700W WO 2007044796 A3 WO2007044796 A3 WO 2007044796A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
calcilytics
calcilytic
pyridazinone compounds
disclosed
Prior art date
Application number
PCT/US2006/039700
Other languages
French (fr)
Other versions
WO2007044796A2 (en
Inventor
Irina Shcherbakova
Camille G Wermuth
Frederick Jeannot
Paola Ciapetti
Virginie Roques
William L Heaton
Jeff A Breinholt
Rebecca L Conklin
Original Assignee
Nps Pharma Inc
Irina Shcherbakova
Camille G Wermuth
Frederick Jeannot
Paola Ciapetti
Virginie Roques
William L Heaton
Jeff A Breinholt
Rebecca L Conklin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Pharma Inc, Irina Shcherbakova, Camille G Wermuth, Frederick Jeannot, Paola Ciapetti, Virginie Roques, William L Heaton, Jeff A Breinholt, Rebecca L Conklin filed Critical Nps Pharma Inc
Publication of WO2007044796A2 publication Critical patent/WO2007044796A2/en
Publication of WO2007044796A3 publication Critical patent/WO2007044796A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Various calcilytic compounds and pharmaceutical compositions containing these compounds are disclosed. Calcilytic compounds are compounds capable of inhibiting calcium receptor activity. Methods for preparing calcilytic compounds, oral bioavailability of calcilytic compounds, and their use as calcium receptor antagonists are also disclosed.
PCT/US2006/039700 2005-10-11 2006-10-11 Pyridazinone compounds as calcilytics WO2007044796A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72534005P 2005-10-11 2005-10-11
US60/725,340 2005-10-11

Publications (2)

Publication Number Publication Date
WO2007044796A2 WO2007044796A2 (en) 2007-04-19
WO2007044796A3 true WO2007044796A3 (en) 2007-12-13

Family

ID=37943504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/039700 WO2007044796A2 (en) 2005-10-11 2006-10-11 Pyridazinone compounds as calcilytics

Country Status (1)

Country Link
WO (1) WO2007044796A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (en) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (en) 2007-07-12 2009-04-02 Merck Patent Gmbh pyridazinone derivatives
DE102007061963A1 (en) 2007-12-21 2009-06-25 Merck Patent Gmbh pyridazinone derivatives
DE102008019907A1 (en) 2008-04-21 2009-10-22 Merck Patent Gmbh pyridazinone derivatives
DE102008028905A1 (en) 2008-06-18 2009-12-24 Merck Patent Gmbh 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives
KR101663335B1 (en) 2008-12-22 2016-10-06 메르크 파텐트 게엠베하 6-1--1--4--2-3-5-2--4----2---2--3- novel polymorphic forms of 6-1-methyl-1h-pyrazol-4-yl-2-3-5-2-morpholin-4-yl-ethoxy-pyrimidin-2-yl-benzyl-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
WO2011017261A1 (en) 2009-08-07 2011-02-10 E. I. Du Pont De Nemours And Company Fungicidal diphenyl-substituted pyridazines
PL2519100T3 (en) 2009-12-29 2017-09-29 Mapi Pharma Limited Intermediate compounds and processes for the preparation of tapentadol and related compounds
WO2012136724A1 (en) 2011-04-06 2012-10-11 Basf Se Substituted pyrimidinium compounds for combating animal pests
JP6115303B2 (en) * 2012-05-18 2017-04-19 Jnc株式会社 Phenol compound having carbonyl group as adjacent group and use thereof
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
KR102136440B1 (en) * 2013-02-21 2020-07-21 스미또모 가가꾸 가부시끼가이샤 Process for producing pyridazinone compound and production intermediates thereof
EP3126362B1 (en) 2014-04-02 2022-01-12 Intermune, Inc. Anti-fibrotic pyridinones
CA3118934A1 (en) 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
TW202102478A (en) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 Novel iron chelators

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999025697A1 (en) * 1997-11-19 1999-05-27 Kowa Co., Ltd. Novel pyridazine derivatives and drugs containing the same as the active ingredient
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
US6680316B1 (en) * 1999-02-26 2004-01-20 Kowa Co., Ltd. Pyridazin-3-one derivatives and medicines containing the same
WO2004046133A1 (en) * 2002-11-15 2004-06-03 Merck Sharp & Dohme Limited Amino-heterocycles as vr-1 antagonists for treating pain
US20040142932A1 (en) * 2002-01-18 2004-07-22 Michael Hepperle Substituted pyridazinones

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
WO1999025697A1 (en) * 1997-11-19 1999-05-27 Kowa Co., Ltd. Novel pyridazine derivatives and drugs containing the same as the active ingredient
US20020123496A1 (en) * 1997-11-19 2002-09-05 Kowa Co., Ltd. Novel pyridazine derivatives and medicines containing the same as effective ingredients
US6680316B1 (en) * 1999-02-26 2004-01-20 Kowa Co., Ltd. Pyridazin-3-one derivatives and medicines containing the same
US20040142932A1 (en) * 2002-01-18 2004-07-22 Michael Hepperle Substituted pyridazinones
WO2004046133A1 (en) * 2002-11-15 2004-06-03 Merck Sharp & Dohme Limited Amino-heterocycles as vr-1 antagonists for treating pain

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [online] ISMAIL ET AL., XP008093047 *
DATABASE REGISTRY [online] XP008093049 *
EGYPT. J. CHEM., vol. 24, no. 4-6, 1982, pages 365 - 369 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones

Also Published As

Publication number Publication date
WO2007044796A2 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
WO2007044796A3 (en) Pyridazinone compounds as calcilytics
PL2054411T3 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
EP1861358A4 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist, and pharmaceutical compositions containing the same
WO2008150118A3 (en) Novel amide derivative for inhibiting the growth of cancer cells
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
HK1120442A1 (en) Novel opioid antagonists
WO2007135529A3 (en) Azabenzimidazolyl compounds as mglur2 potentiators
WO2007120284A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007076260A3 (en) Farnesoid x receptor agonists
UA92670C2 (en) Pyrazoline compounds as mineralocorticoid receptor antagonists , pharmaceutical use thereof, composition based thereon
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
WO2004041755A3 (en) Quinazolinone compounds as calcilytics
WO2010011821A3 (en) Dual-acting antihypertensive agents
WO2008121348A3 (en) Peripheral opioid receptor antagonists and uses thereof
WO2007114855A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007073303A3 (en) Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors
TW200639156A (en) New compounds
GEP20104880B (en) Carboxamide derivatives as muscarinic receptor antagonists
WO2007062370A3 (en) Calcilytic compounds
EP2238105A4 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
PL1831191T3 (en) Chroman derivatives and their use as 5-ht receptor ligands
IL179530A0 (en) Novel compounds, pharmaceutical compositions containing same and methods of use for same
WO2007098273A3 (en) Novel crystalline forms of armodafinil and preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06825754

Country of ref document: EP

Kind code of ref document: A2